Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forte Biosciences, Inc.FBRX · Entity 9529 | See remarks | January 01, 2024 | January 03, 2024 |
| Metacrine, Inc.MTCR · Entity 115177 | Chief Medical Officer | May 20, 2021 | May 20, 2021 |
| Pfenex Inc.PFNX · Entity 146052 | See Remarks | February 01, 2018 | February 02, 2018 |
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Chief Medical Officer | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forte Biosciences, Inc.
Report date January 01, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 93,405 |
Ending reported balance
After 2024-01-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-01 · Exercise / conversion · Acquired 7,500 · Balance 96,478 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Row 2 · 2024-01-01 · Tax withholding · Disposed 3,073 · Balance 93,405 F2: On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 90,000 |
Reported balance
After 2024-01-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-01 · Exercise / conversion · Disposed 7,500 · Balance 90,000 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
F2: On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld.
F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.
Metacrine, Inc.
Report date May 20, 2021 · Filed May 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,289 |
Reported balance
After 2021-05-20 transaction · row 1
1 source rowRow 1 · 2021-05-20 · Purchase · Acquired 3,289 · Balance 3,289 |
Pfenex Inc.
Report date February 01, 2018 · Filed February 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.38 · Expires 2028-02-01 | Direct | 78,407 |
Reported balance
After 2018-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-01 · Grant · Acquired 78,407 · Balance 78,407 F1: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2018.
Viking Therapeutics, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.27 · Expires 2036-06-01 | Direct | 190,000 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 190,000 · Balance 190,000 F1: 25% of the shares subject to the option vested immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vested immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 23:44 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $31.27 | $0.00 |
DisclosureSEC source: 0001193125-26-256039 · ownership.xml · derivative · entry 1 Chen Hubert C · CIK 0001622297 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2036-06-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vested immediately, and 25% of the shares subject to the option will vest on each one-year anniversary of the grant date over the next three years. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:04 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000326 · doc4.xml · derivative · entry 3 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:04 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Tax withholdingCommon Stock | 3,073 | $0.82 | $2,525.08 |
DisclosureSEC source: 0001209191-24-000326 · doc4.xml · nonDerivative · entry 2 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,405 F2 · price: On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:04 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000326 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:29 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051484 · doc4.xml · derivative · entry 3 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:29 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Tax withholdingCommon Stock | 2,593 | $0.66 | $1,716.57 |
DisclosureSEC source: 0001209191-23-051484 · doc4.xml · nonDerivative · entry 2 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,978 F2 · price: On October 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on September 29, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:29 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051484 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:58 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantCommon Stock | 74,257 | $1.01 | $74,999.57 |
DisclosureSEC source: 0001209191-23-044282 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,071 Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:08 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-040978 · doc4.xml · derivative · entry 3 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:08 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Tax withholdingCommon Stock | 2,593 | $1.04 | $2,696.72 |
DisclosureSEC source: 0001209191-23-040978 · doc4.xml · nonDerivative · entry 2 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,814 F2 · price: On July 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on June 30, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 20:08 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-040978 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:17 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023076 · doc4.xml · derivative · entry 3 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:17 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Tax withholdingCommon Stock | 2,593 | $1.01 | $2,618.93 |
DisclosureSEC source: 0001209191-23-023076 · doc4.xml · nonDerivative · entry 2 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,907 F2 · price: On April 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on March 31, 2023 was the settlement price used to calculate the shares withheld. Read SEC document |
| April 01, 2023 Filed Apr 5, 2023 00:17 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023076 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 01:15 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantRestricted Stock Units · Derivative | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013450 · doc4.xml · derivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. F2 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:24 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001209191-22-035031 · doc4.xml · derivative · entry 1 Chen Hubert C · CIK 0001622297 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Inducement Equity Incentive Plan) through each applicable vesting date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total shares subject to the option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 7, 2022. Read SEC document |
| May 20, 2021 Filed May 20, 2021 22:54 UTC | Metacrine, Inc. MTCR · Entity 115177 | PurchaseCommon Stock | 3,289 | $3.60 | $11,840.40 |
DisclosureSEC source: 0001209191-21-034595 · doc4.xml · nonDerivative · entry 1 Chen Hubert C · CIK 0001622297 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,289 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:01 UTC | Metacrine, Inc. MTCR · Entity 115177 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $10.09 | $0.00 |
DisclosureSEC source: 0001209191-21-010204 · doc4.xml · derivative · entry 1 Chen Hubert C · CIK 0001622297 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on the one year anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter until fully vested on February 10, 2025. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 20:06 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 78,407 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000899243-18-002749 · doc4.xml · derivative · entry 1 Chen Hubert C · CIK 0001622297 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,407 Underlying: Common Stock · 78,407 shares Expires 2028-02-01 F1 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest and become exercisable on the one year anniversary of the Vesting Commencement Date and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date, subject to the reporting person continuing to be a Service Provider (as such term is defined in the Issuer's 2014 Equity Incentive Plan) through each such date. "Vesting Commencement Date" shall mean February 1, 2018. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 17:11 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0000899243-17-006107 · doc4.xml · derivative · entry 1 Chen Hubert C · CIK 0001622297 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-03-01 F1 · derivative.exercise_date: 25% shall vest on the one year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean March 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.